FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

J ,			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  McCourt Marion				RE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]									all appli Directo Officer	or (give title		10% Ow Other (s	ner	
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD				3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022									X Officer (give fine Other (specify below)  EVP Commercial						
(Street) TARRY			10591 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting     Person						
Table I - Non-Deriv  1. Title of Security (Instr. 3)  2. Transa Date (Month/L				action	ction 2A. De Execu ay/Year) if any		A. Deemed execution Date,		3. Transaction Code (Instr.		Sed of, or Benefic Securities Acquired (A) Sposed Of (D) (Instr. 3, 4		Ť	5. Amount of Securities Beneficially Owned Followi		Form (D) or	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)		[	Instr. 4)
Common Stock		01/03	1/03/2022				M <sup>(1)</sup>		1,000	A	\$342	.93	20	20,644		D			
Common	Common Stock		01/03	01/03/2022				S <sup>(1)</sup>		1,000	D	\$62	25	19	19,644		D		
Common Stock													116			I 4	3y 401(k) Plan		
		7	able II -								osed of converti				wned		,		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		n Date,	4. Transaction Code (Instr 8)		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		e	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares	r					
Non- Qualified Stock Option (right to	\$342.93	01/03/2022			M <sup>(1)</sup>			1,000	(2)		02/12/2028	Common Stock	1,000		\$0.0	9,000		D	

## Explanation of Responses:

- $1.\ Disposition/acquisition\ made\ pursuant\ to\ a\ plan\ intended\ to\ comply\ with\ Rule\ 10b5-1(c).$
- $2. \ The stock option award vests in four equal annual installments, commencing one year after the date of grant.\\$

<u>/s/\*\* Marion McCourt</u> <u>01/04/2022</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.